Scribe Therapeutics
PrivateLast Round
Grant
Jun 18, 2026
Est. Valuation
$300M
Total Funding Raised
$175M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Scribe Therapeutics is a biotechnology company that develops engineered CRISPR technologies and genetic medicines aimed at treating genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Scribe Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Scribe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 18, 2026 | ||||
| Convertible Debt | May 16, 2023 | ||||
| Series B | Mar 31, 2021 | ||||
| Series A | Oct 6, 2020 |
Key People
Founding team and executive leadership
Scribe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, Series A |
| RA Capital Management | Series B |
| Perceptive Advisors | Series B |
| Avoro Ventures | Series B |
| Avoro Capital | Series B |
| OrbiMed | Series B |
| T. Rowe Price | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors grew 49% MoM, from 7.4K to 11K.
- Apr 30, 2026
Will attend EAS Congress 2026 to highlight CRISPR platform advances.
Scribe Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Scribe Therapeutics's valuation, stock price, and market status.